Abstract: Insulin preparations comprising an insulin compound or a mixture of two or more insulin compounds, a nicotinic compound and an amino acid.

Abstract: Protracted GLP-1 compounds and therapeutic uses thereof.

Abstract: The present invention relates to a pharmaceutical composition comprising a GLP-1 derivative having a lipophilic substituent; and a surfactant.

Abstract: Novel protracted exendin-4 compounds and therapeutic uses thereof.

Abstract: Method for increasing half-life of therapeutic agents in plasma and novel polypeptide derivatives.

Abstract: Novel protracted GLP-1 compounds and therapeutic uses thereof.

Abstract: A pharmacologically active peptide hormone derivative in which the parent peptide hormone has been modified by introducing either a lipophilic substituent, W, in the N-terminal amino acid or a lipophilic substituent, Z, in the C-terminal amino acid of the parent peptide hormone or an analogue thereof, said lipophilic substituent having from 8 to 40 carbon atoms, has a protracted profile of action.

Abstract: A polymer substrate functionalized with a functionality comprising at least one cyclic, metal ion coordinating ligand group, the cyclic ligand group comprising at least 3 metal ion coordinating donor atoms independently selected from the group consisting of N, O and S.

Abstract: This invention relates to a life saving medicament for critically ill patients and a method of treatment. The composition is a pharmaceutically effective amount of a blood glucose regulator which is used to control the blood glucose level.

Abstract: Stable insulin formulations can be prepared by mixing a monomeric insulin and a soluble acylated insulin analog.

Abstract: The present invention provides a method for acylating one or more amino groups of a peptide where the acylation reaction is to be performed in an aqueous mixture containing less than 10% w/w aprotic polar solvent.

Abstract: The present invention relates to a pharmaceutical composition comprising a GLP-1 derivative having a lipophilic substituent; and a surfactant.

Abstract: The present invention relates to insulin derivatives in which a lipophilic group having from 12 to 40 carbon atoms is attached to the ?-amino group of the N-terminal amino acid in the B-chain or to the carboxy group of the C-terminal amino acid in the B-chain have a protracted profile of action.

Abstract: Process for microfiltration at elevated temperature.

Abstract: The present invention relates to novel derivatives of exendin-4 or exendin-4 fragments, wherein the derivatives have a lipophilic substituent attached, optionally via a spacer, to an amino acid residue, which is not the N-terminal or C-terminal amino acid residue of the derivative.

Abstract: The present invention relates to a method for in vitro maturation of oocytes comprising the steps of: (a) culturing one or more GV oocytes in a culture medium, the culture medium comprising a nuclear maturation inhibiting substance and comprising one or more gonadotropins and/or one or more growth factors, the culturing taking place for a time period sufficient for cytoplasmatic maturation to occur; (b) washing the GV oocytes of step (a) to remove the nuclear maturation inhibiting substance; (c) culturing the washed oocytes of step (b) in a culture medium comprising one or more gonadotropins and/or one or more growth factors and/or MAS for a time period sufficient for nuclear maturation. The invention also relates to an oocyte culture medium comprising a nuclear maturation inhibiting substance and comprising one or more gonadotropins and/or one or more growth factors.

Abstract: A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any diseases and disorders, wherein a glucagon antagonistic action is beneficial, such as hyperglycemia, Type 1 diabetes, Type 2 diabetes, disorders of the lipid metabolism, such as dyslipidemia, and obesity.

Abstract: Methods and uses for treatment of dyslipidemia comprising administration of a GLP-1 compound and another antidyslipidemic drug.

Abstract: A process for producing cation crystals of growth hormone or growth hormone derivatives, as well as growth hormone and growth hormone derivatives. The process of producing the growth hormone crystals includes the steps of (a) adding cations of inorganic or organic nature and an organic solvent or a mixture of inorganic solvents at a pH between 5.0 and 6.8 to a solution of growth hormone or derivatives. (b) growing growth hormone crystals at a temperature from about 0 to 30° C. and (c) isolating the cation crystals.

Abstract: Disclosed is a method of preparing zinc free rapid acting insulin analogue. In one embodiment insulin crystals are prepared by providing a solution of an analogue having a pH between 7 and 9.5. The solution is mixed with a salt of an alkali metal or salt and formed crystals are recovered.